Status:
COMPLETED
PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
Lead Sponsor:
University of Minnesota
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Borderline Personality Disorder
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan...
Detailed Description
The primary objective of this proposed study will be to compare the baseline PET scan to the endpoint scan in 15 BPD patients who have been treated with olanzapine. The comparison of the scans will be...
Eligibility Criteria
Inclusion
- Age 18-45 years
- Diagnosis: borderline personality disorder by DSM-IV criteria
- Gender: Female
- May have history of substance use and other Axis II disorders
Exclusion
- Axis I diagnosis of schizophrenia, schizoaffective disorder, or bipolar I disorder during the subject's lifetime. No current major depression or PTSD.
- Treatment with psychotropic medication in the previous month.
- Medical disorder that would influence outcome of the study - e.g. epilepsy, thyroid disease, HIV, etc.
- Medical disorder that would not allow use of olanzapine
- Active substance abuse or dependence
- Previous adverse reaction to olanzapine
- Females whom are pregnant or nursing
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00275301
Start Date
December 1 2005
End Date
December 1 2008
Last Update
May 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota, Dept of Psychiatry
Minneapolis, Minnesota, United States, 55454